ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,662.32
      0.27%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Prime Medicine Inc (PRME)

      7. Prime Medicine Inc (PRME) News

      PRME

      Prime Medicine (PRME)

      Prime Medicine Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PRME
      DateTimeSourceHeadlineSymbolCompany
      05/30/20248:00AMGlobeNewswire Inc.Prime Medicine to Present at Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
      05/21/20244:06PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PRMEPrime Medicine Inc
      05/21/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
      05/13/20248:00AMGlobeNewswire Inc.Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:PRMEPrime Medicine Inc
      05/10/20248:22AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRMEPrime Medicine Inc
      05/10/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
      05/10/20248:00AMGlobeNewswire Inc.Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
      05/08/20248:00AMGlobeNewswire Inc.Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
      05/01/20248:00AMGlobeNewswire Inc.Prime Medicine to Participate in the 27th Annual Milken Institute Global ConferenceNASDAQ:PRMEPrime Medicine Inc
      04/29/20247:00AMGlobeNewswire Inc.Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
      04/23/20248:00AMGlobeNewswire Inc.Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsNASDAQ:PRMEPrime Medicine Inc
      03/01/20248:09AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRMEPrime Medicine Inc
      03/01/20248:04AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRMEPrime Medicine Inc
      03/01/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
      03/01/20248:00AMGlobeNewswire Inc.Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
      02/28/20248:00AMGlobeNewswire Inc.Prime Medicine to Participate in Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
      02/23/20245:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
      02/23/20245:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
      02/22/20249:31PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PRMEPrime Medicine Inc
      02/20/20245:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
      02/20/20244:01PMGlobeNewswire Inc.Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:PRMEPrime Medicine Inc
      02/16/20246:23AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
      02/16/20246:17AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
      02/14/202411:50PMGlobeNewswire Inc.Prime Medicine Announces Pricing of Upsized Public OfferingNASDAQ:PRMEPrime Medicine Inc
      02/14/20249:57PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PRMEPrime Medicine Inc
      02/14/20245:27PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
      02/14/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
      02/14/20244:05PMGlobeNewswire Inc.Prime Medicine Announces Proposed Public Offering of Common StockNASDAQ:PRMEPrime Medicine Inc
      01/25/20248:00AMGlobeNewswire Inc.Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisNASDAQ:PRMEPrime Medicine Inc
      01/08/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
       Showing the most relevant articles for your search:NASDAQ:PRME